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It is well recognized that the incidence of heart failure and the risk of death is high in diabetic patients
after myocardial infarction (MI). Accumulating evidence showed that puerarin (PUE) has protecting
function on both cardiovascular disease and diabetes. The aim of this study is to explore whether
puerarin could improve cardiac function in diabetic mice after MI and the underlying mechanism. The
left anterior of Streptozotocin (STZ)-Nicotinamide (NA) induced diabetic mice were ligated permanently
except for the Shame group. Then the operated mice were randomly treated with PUE or saline. Cardiac
function was evaluated by echocardiograph before and at 1, 2, 4 weeks after MI. GLUT4/CD36/p-Akt/PPAR
a of the heart was examined after treatment for 4 weeks. The results indicated that PUE signiﬁcantly
increased survival rate, improved cardiac function compared with MI group. Moreover, PUE increased
expression and translocation of GLUT4 while attenuated expression and translocation of CD36. Western
blot analysis showed that PUE enhanced phosphorylation of Akt and decreased PPAR a. This study
demonstrated that PUE improved cardiac function after MI in diabetic mice through regulation of energy
metabolism, the possible mechanism responsible for the effect of PUE was increasing the expression and
translocation of GLUT4 while attenuating the expression and translocation of CD36.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Diabetes Mellitus (DM) is widely known to increase the
morbidity and mortality of cardiovascular disease [1,2]. Compared
with nondiabetic patients, diabetic patients are twice likely to die
after MI [3]. In addition, diabetic patients have higher incidence of
heart failure (HF) after MI even underwent traditional treatment
and primary angioplasty [4]. However, potential mechanisms
leading to increased risk of HF in diabetic patients following MI is
still not well illustrated. Meanwhile, recent evidences indicated
that energy metabolism of heart played a role in it. Heart is an
engine requiring continuous supply of energy, and the major en-
ergy substrates for heart are fatty acid (FA) and glucose. Previous
researches have showed that normal heart can switch its energy
substrates from FA to glucose rapidly under hypoxia [5]. On theg).
Inc. This is an open access article uopposite, diabetes has an adverse effect on cardiac energy meta-
bolism that it shows suppression on glucose consumption but
reliance on fatty acid [6]. Increasing evidences have suggested that
this conﬂicting cardiac energy metabolism may have a role in the
progression of heart dysfunction both in acute and long-term
setting in diabetes after MI. Restoration of cardiac energy meta-
bolism may protect the heart. In heart, energy substrate uptake is
dependent on the sarcolemmal presence of fatty acid and glucose
transporters. GLUT4 is the main transporters for glucose [7] while
CD36 is for FA [8]. Therefore, it is predicted that increasing sarco-
lemmal GLUT4 or attenuating sarcolemmal CD36 may exert a
beneﬁcial effect on cardiac function.
Puerarin, as the major active component isolated from the root
of traditional Chinese medicine pueraria lobata, possesses a series
of beneﬁcial activities on cardiovascular diseases such as myocar-
dial infarction [9] and hypertension [10]. It was reported that PUE
has good effect on diabetes [11e13]. Especially, PUE could regulate
energy metabolism of the whole body and enhanced soleus musclender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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was no study on whether PUE could ameliorate the prognosis of
diabetes following MI through regulation of metabolism of heart.
Therefore, the objective of this study was to investigate that PUE
could regulate metabolism of heart and had protecting function on
diabetes following MI.
2. Materials and methods
2.1. Animal and induction of diabetes
The experiments were performed in accordance with Labora-
tory Animal Center of the Nanjing Medical University on the care
and use of Laboratory Animal and were approved by the Ethics
Review of Lab Animal Use Application of Nanjing Medical Univer-
sity. DM was induced in adult C57BL/6J male mice (obtained from
Laboratory Animal Center of Nanjing University), weight 18e22 g
by intraperitoneal (i.p) injection of streptozocin (STZ; Sigma, St
Louis, USA) and Nicotinamide (NA; Sigma, St Louis, USA). In brief,
mice received STZ (STZ was diluted in 0.1 M citric acid buffer at the
time of use, PH 4.5) after fasted for 16 h at 100 mg/kg, i.p twice on
day 0 and day 2.15 min before administration of STZ, NA (NA was
dissolved in saline at the time of use) was injected at 120 mg/kg i.p
[14]. The tail vein fasting blood glucose (FBG) concentration was
measured by glucose oxidase method (Glucose Analyzer; Roche,
Mannheim, Germany) on day 9 after mice were fasted for 12 h. DM
was conﬁrmed if fasting glucose levels were equal to or higher than
11.1 mM.
2.2. Experimental model of myocardial infarction
Myocardial infarction was generated by surgical ligation of LAD
coronary artery refer to previous description [15]. Brieﬂy, Initial
anesthesis was performed with intraperitoneal injection of
pentobarbital sodium (50 mg/kg). After ﬁxed in supine position,
mice were incubated with a tracheal cannula. Then the chest cavity
was opened to expose the heart, a 8-0 silk suture was used for
permanent ligation of LAD coronary artery. The suture was passed
approximately 2e3 mm below the tip of the left auricle. The thorax
was closed layer by layer with 6e0 silk suture. During the process of
operation, the electrocardiogram (ECG) was applied to continu-
ously monitor the heart rate. MI was conﬁrmed by ST-segment
elevation and the pale color of the anterior wall of the left
ventricle (LV). Body temperature was maintained by a heating pad.
After operation, the mice were put on an electric blanket for re-
covery. Penicilin was injected for prevention of infection and
analgesic for easing pain.
2.3. Administration of PUE
PUE was purchased from Shandong Fangming pharmaceutical
company (Shandong, China). A fresh solution was prepared by
diluting in saline. The survived MI mice were randomized treated
with PUE (100 mg/kg, n ¼ 20) and saline (n ¼ 20) intraperitoneal
once a day for 4 weeks. The Shame group was given equal saline.
After 4 weeks, all mice were sacriﬁced by carbon dioxide (CO2).
2.4. Echocardiography
Heart function was estimated using a high-frequency ultra-
sound system Vevo2100 (VisuaSonic Inc, Toronto, ON, Canada) with
a 30 MHz central frequency scan head as described previously [16].
Before and at 1, 2, 4 weeks after MI, anesthesia was performed with
1e2% isoﬂurane vapor. The echocardiographic images in short and
long axes were obtained on the condition of monitoring respirationrate, heart rate and ECG by 2 experienced and independent oper-
ators blinded to the experiments. The left ventricular ejection
fraction(LVEF) and left ventricular fractional shortening(LVFS) were
calculated by estimated parameters include left ventricular end-
systolic diameter (LVESd), left ventricular end-diastolic diameter
(LVEDd), left ventricular posterior wall end-systolic thickness
(LVPWTs), left ventricular posterior wall end-diastolic thickness
(LVPWTd), interventricular septum end-systolic thickness (IVSd)
and interventricular septum end-diastolic thickness (IVSs).
2.5. Immunohistochemistry
Immunohistochemistry was applied to determine the distribu-
tion of GLUT4 and CD36. The diabetic mice were perfused with
20 ml of 0.01 M PBS followed by 30 ml of 4% paraformaldehyde
after anesthetized. The hearts were then dipped into 4% para-
formaldehyde for 24 h at 4 C after dissected out and were trans-
ferred to 30% sucrose solution overnight at 4 C. Mounted with OCT
Compound (Sakura Finetek, Torrance, CA), the specimens were
frozen quickly and cut into 6 mm-thick slice. The sections were
incubated with blocking buffer (Beyotime, China). After incubated
with primary antibody against GLUT4 (Abcam, ab65267, 1:200) and
CD36 (Abcam, ab80080, 1:200) overnight at 4 C, Alexa Fluor-
conjugated secondary antibodies (Invitrogen) were applied for
1 h. The representative images were shot by a ﬂuoresence micro-
scopy (Nikon, Japan).
2.6. Western blotting evaluation
Total protein was isolated from the heart tissue according to the
standard protocols while membrane protein was obtained by using
Mem-PER™ Eukaryotic Membrane Protein Extraction Reagent Kit
(Thermo, 89826) referring to the instructions. Protein concentra-
tion was quantiﬁed by BCA Protein Assay Kit (KeyGEN BioTECH,
China). 20 mg protein lysate was utilized for western blotting with
primary antibodys against GLUT4 (1:1000), CD36 (1:1000), PPAR a
(Abcam, ab8934, 1:1000), Akt (Abcam, ab6076, 1:1000), p-Akt
(Abcam,ab8932, 1:1000). The blots were developed with a chem-
iluminescence system (Tanon, Shanghai, China) and then quanti-
ﬁed by densitometry.
2.7. Analysis of data and statistic
Continuous variables were presented as mean ± standard de-
viation (SD). KaplaneMeier curves were used for analysis of sur-
vival rate of diabetic mice after MI and log-rank test was used for
comparison. One-way ANOVA or Student's t test was used for
determination of the difference between groups and statistical
signiﬁcance was set as p < 0.05. SPSS 13.0 or Graphpad Prism 5.0
was used for analysis of all data.
3. Results
3.1. Basic parameters
No major differences were found between groups in terms of
body mass, blood glucose, heart rate, LVEF before operation
(Table 1).
3.2. PUE raises survival rate
More than half of the mice died in MI group 4 weeks after
ligation. Survival rate was raised in PUE treated group compared
with untreated MI group (log-rank test, p ¼ 0.048; Fig. 1 A). Post-
mortem examination showed that the main cause of death was HF.
Table 1
Basic parameters of the mouse.
Basic parameters Shame(n ¼ 10) MI(n ¼ 20) MI þ PUE(n ¼ 20) P Value
Body mass(g) 19.30 ± 0.95 19.60 ± 0.70 19.00 ± 0.94 0.32
Blood glucose(mmol/l) 17.68 ± 3.15 18.02 ± 2.39 16.97 ± 3.29 0.73
Heart rate(per min) 439.40 ± 81.55 466.60 ± 55.84 453.20 ± 90.55 0.74
LVEF(%) 62.30 ± 3.47 61.60 ± 3.69 63.31 ± 3.60 0.57
Values are presented as mean ± SD.
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The representative M-mode echocardiograms of diabetic mice
showed that motion range of the left ventricular anterior wall wasFig. 1. Beneﬁcial effects of PUE on prognosis of diabetic mice after MI. (A) survival rate o
mortality in PUE treated mice than in untreated mice (log-rank: P ¼ 0.048) (B)Representat
ventricular ejection fraction(LVEF) in diabetic mice at 1, 2, 4 week after MI. (D) Analysis of le
per group. *p < 0.05 MI versus Shame group, þp < 0.05 MI þ PUE versus MI group.weakened at 1week after operation. After 4weeks, the abnormality
of anterior wall movement was more serious in MI group. The
motion range of the left ventricular anterior wall was much better
in PUE treated group compared with MI group (Fig. 1B). LVEF andf diabetic mice 4 weeks after MI. KaplaneMeier analysis showed signiﬁcantly lower
ive M-mode echocardiograms of diabetic mice before and after MI. (C)Analysis of left
ft ventricular fractional shortening(LVFS) in diabetic mice at 1, 2, 4 week after MI. n ¼ 8
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Compared with Shame group, LVEF and LVFS were signiﬁcantly
decreased in MI group 1 week after MI. PUE group showed signif-
icantly increase in LVEF and LVFS compared with MI group 4 weeks
after MI (Fig. 1C and D).
3.4. PUE increased expression of GLUT4 and promoted translocation
of GLUT4 in diabetic mice heart after MI
After 4 weeks of MI, we harvested the heart of the diabetic mice
and Immunoﬂuorescence was conducted to determine the distri-
bution of GLUT4. The results revealed that GLUT4 was located in
intracellular plasm as well as on the cell surface. Moreover, GLUT4
mainly anchored on the cell membrane. The expression of GLUT4
was increased in the two MI groups compared with the Shame
group. In addition, GLUT4 at cell surface were promoted in MI
groups. However, the expression and translocation of GLUT4 in PUE
treated group were signiﬁcantly higher than untreated MI group
(Fig. 2A). Western blots showed that total protein of GLUT4 as well
as GLUT4 on the cell membrane (mGLUT4) were all increased after
MI. GLUT4 and mGLUT4 were higher in PUE treated group
compared with MI group (Fig. 2B and C).
3.5. PUE decreased expression and translocation of CD36 in diabetic
mice heart after MI
Immunoﬂuorescence was conducted to determine the distri-
bution of CD36. The outcomes revealed that CD36 was located in
cytoplasm as well as on the cell surface. Moreover, CD36 mainly
anchored on the cell membrane. The expression and sarcolemmalFig. 2. Effects of PUE on the expression and translocation of GLUT4 in the myocardium of the
mice at 4 week after MI, GLUT4 was labeled with FITC (green) and nuclei were labeled w
membrane GLUT4 (mGLUT4). GAPDH serves as an internal Control. (C) Semiquantitative an
color in this ﬁgure legend, the reader is referred to the web version of this article.)CD36 were attenuated in the diabetic mice 4 weeks after MI
whether treated with PUE or not. Treatment of PUE reduces the
expression and translocation of CD36 (Fig. 3A). Total protein CD36
as well as CD36 on the cell membrane (mCD36) were all decreased
afterMI. CD36 andmCD36were less in PUE treated group approved
by western blots (Fig. 3B and C).3.6. PUE increases the phosphorylation of Akt and decrease PPAR a
Western blot was applied to detect the expression of p-Akt and
PPAR a. Analysis indicated that there was no signiﬁcant difference
in MI and Shame group. PUE treatment signiﬁcantly increased the
phosphorylation of Akt in the cardiac tissue of diabetic mice after
MI. Furthermore, the expression of PPAR a was signiﬁcantly
reduced by PUE (Fig. 4).4. Discussion
More than one hundred years ago, a strong relationship be-
tween diabetes and heart failure was already established. Ischemic
heart disease usually results in an increased risk of heart failure in
patients of diabetes. Potential mechanisms leading to increased risk
of HF in diabetic patients following MI is multifactorial [5]. Alter-
ation in myocardial energy metabolism takes a part in it [17].
Traditional strategies for prevention and treatment of HF mainly
focus on reducing the risk related to HF and diabetes, but no
therapy present satisfying performance so far. As far as we know,
there was no therapy taking myocardial energy metabolism as a
target to treat HF in diabetes following MI.diabetic mice after MI. (A) Immunoﬂuorence stainning of myocardial tissue of diabetic
ith DAPI (blue). (B) Western blots analysis reveals the expression of total GLUT4 and
alysis of GLUT4 and mGLUT4. n ¼ 6 per group. (For interpretation of the references to
Fig. 3. Effects of PUE on the expression and translocation of CD36 in the myocardium of the diabetic mice after MI. (A) Immunoﬂuorence stainning of myocardial tissue of diabetic
mice at 4 week after MI, CD36 was labeled with FITC (green) and nuclei were labeled with DAPI (blue). (B) Western blots analysis reveals the expression of total CD36 and
membrane (mCD36). GAPDH serves as an internal Control. (C) Semiquantitative analysis of the expression of CD36 and mCD36. n ¼ 6 per group. (For interpretation of the references
to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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diseases for decades. Meta-analysis suggested that PUE injection
may exert protective effect on unstable angina [18]. Animal models
also conﬁrmed that PUE could protect the heart post MI [9]. In
recent years, PUE was applied to treat complications of diabetes.
Another Meta-analysis concludes that PUE was effective in treat-
ment of diabetic peripheral neuropathy [19]. What is more, PUEFig. 4. Summary of the expression of p-Akt and PPAR a in the myocardium of the diab
phosphorylation of Akt. (B) Densitometry ratio of the expression of P-Akt and Akt. (C) We
Semiquantitative analysis of the expression of PPAR a. n ¼ 6 per group.could regulate energy metabolism of the whole body and enhanced
the uptake of glucose [12] in STZ-induced diabetic rats.
The myocardium requires a highly efﬁcient energy generation
system to maintain the contractile performance. To adapt the
enormous demands of energy, the heart takes a wide range of
substrates as its energy sources mainly includes FA and glucose,
and it expresses a high level of glucose and fatty acid transporters.etic mice after MI. (A) Western blots analysis indicated PUE treatment increase the
stern blots analysis show that PUE treatment decreased the expression of PPAR a. (D)
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utilization and CD36 is the primary transporter for FA in heart. In
cardiac selective GLUT4 deﬁciency mice, glucose utilization was
limited during ischemia [20]. Over expression of GLUT4 in db/db
mice improve the utilization of glucose [6,21]. Coburn Et.al found
that FA uptake was decreased in CD36 null mice [22]. While over
expression of CD36 increased FA uptake [23]. Hence, Glucose and
FA were taken up into the cardiomyocyte via GLUT4 and CD36
respectively. In this study, GLUT4 and CD36 were selected as in-
dicators of glucose and FA metabolism of heart and both total
protein and sarcolemmal transporters were detected. The
myocardium has a great ﬂexibility to switch between glucose and
FA fuels according to requirements and surrounding conditions to
high-efﬁciently produce ATP, which is the foundation of sustaining
cardiac mechanical performance. Glucose transport and utilization
was increased and FA transport and utilization was decreased un-
der hypoxia [24,25]. GLUT4 and CD36mediated transport represent
a mechanism [20]. It was found in this study that the expression
and translocation of GLUT4 were increased while the expression
and translocation of CD36 were decreased in heart 4 weeks after
ligation whether treated with PUE or not, which was adaptive
alteration of the heart in ischemia condition. Disturbance of this
ability will inevitably lead to impairment of cardiac function [26]. In
diabetes, GLUT4 translocation in cardiomyocyte was depleted or
diminished and the expression of CD36 was increased [27], which
decreased glucose consumption and augment the consumption of
FA. The alterations of energy metabolism of diabetic heart could
severely damage its ﬂexibility and have detrimental consequences
[28]. In this study, the changes of GLUT4 and CD36 were slight in
the MI group as a result of diabetes compared with Shame group.
The decreased glucose consumption and augmented FA consump-
tion caused decreased cardiac efﬁciency and worse cardiac
dysfunction. It is expected that normalization of the energy meta-
bolism will improve cardiac function [29e31]. In our study, sarco-
lemmal location of GLUT4 was remarkably improved and CD36 at
the cell surfacewas attenuated in PUE treated group. Changes of the
two transporters in the study implied energy substrates switch
from FA to glucose in cardiomyocyte, which reduced cardiac oxygen
consumption and increased cardiac efﬁciency. As results, survival
rate was raised and cardiac function was improved signiﬁcantly.
Our results were in line with previous studies that over expression
of GLUT4 in db/db mice improve cardiac function following by
normalizing energy metabolism [6,21]. Increased cardiac fatty acid
supply following by increased sarcolemmal presence of FA trans-
port CD36 are associated with and contribute to impaired cardiac
function, CD36 deﬁciency mice can reverse the cardiac dysfunction
[32].
To explore the underlying mechanism of PUE on the GLUT4 and
CD36, p-Akt/Akt and PPAR a was detected. Several studies have
shown that PI3K/Akt pathway has a great impact on the expression
and translocation of GLUT4 in peripheral tissue [33]. It was found in
this study, PUE enhanced phophorylation of Akt signiﬁcantly in
heart. Despite the relationship between p-Akt and GLUT4 is
conﬁrmed in the peripheral tissue [33], theway how p-Akt regulate
GLUT4 is still need for further study in heart. PPAR a is awell known
regulator of cardiac FA uptake and utilization [34]. PPAR a in heart
was activated in almost all diabetic animal models [34e36].
Agnieszka K et al. found in their study that stimulation of PPAR a
increase the transcript CD36 mRNA content and induced the
translocation of CD36 from intracellular pools to cell membrane
[37]. In our present study, PPAR awas decreased by PUE, whichmay
lead to the changes of CD36. Moreover, down regulation of PPAR a
is suggested essential for the maintenance of cardiac function [38].
In addition, GLUT4 and CD36 is likely to inﬂuence each other
described as the “glucose fatty-acid cycle” by Randle et al. [39].To our best of knowledge, this is the ﬁrst study to report that
PUE could improve cardiac dysfunction in diabetes following MI
through regulation of energy metabolism of heart. Our work may
pave a new way to investigate the therapy for treatment of HF. In
conclusion, the main ﬁndings of the present study were that PUE
treatment improved cardiac dysfunction of diabetic mice after MI.
This was partially accompanied by regulation of energy meta-
bolism. The responsible mechanism was through the PI3K/Akt and
PPAR a pathway.
Conﬂict of interest
None declared.
Acknowledgments
This work was supported by the National Natural Science
Foundation of China (No. 81170102/H0203), the Chinese Medical
Association of the Sunlight Foundation (SCRFCMDA201217), and
the Fourth Period Progect ‘‘333’’ of Jiangsu Province (BRA2012207),
China, Supporting program of Science and Technology of Jiangsu
(Social Development, BK2010021).
Transparency document
Transparency document related to this article can be found
online at http://dx.doi.org/10.1016/j.bbrc.2015.06.067.
References
[1] M. Chiha, M. Njeim, E.G. Chedrawy, Diabetes and coronary heart disease: a risk
factor for the global epidemic, Int. J. Hypertens. 2012 (2012) 697240.
[2] W.L. Lee, A.M. Cheung, D. Cape, B. Zinman, Impact of diabetes on coronary
artery disease in women and men: a meta-analysis of prospective studies,
Diabetes Care 23 (2000) 962e968.
[3] S.M. Donahoe, G.C. Stewart, C.H. McCabe, S. Mohanavelu, S.A. Murphy,
C.P. Cannon, E.M. Antman, Diabetes and mortality following acute coronary
syndromes, JAMA 298 (2007) 765e775.
[4] N. Carrabba, R. Valenti, G. Parodi, G.M. Santoro, D. Antoniucci, Left ventricular
remodeling and heart failure in diabetic patients treated with primary an-
gioplasty for acute myocardial infarction, Circulation 110 (2004) 1974e1979.
[5] J.D. Estep, D. Aguilar, Diabetes and heart failure in the post-myocardial
infarction patient, Curr. Heart Fail Rep. 3 (2006) 164e169.
[6] D.D. Belke, T.S. Larsen, E.M. Gibbs, D.L. Severson, Altered metabolism causes
cardiac dysfunction in perfused hearts from diabetic (db/db) mice, Am. J.
Physiol. Endocrinol. Metab. 279 (2000) E1104eE1113.
[7] A. Zorzano, L. Sevilla, M. Camps, C. Becker, J. Meyer, H. Kammermeier,
P. Munoz, A. Guma, X. Testar, M. Palacin, J. Blasi, Y. Fischer, Regulation of
glucose transport, and glucose transporters expression and trafﬁcking in the
heart: studies in cardiac myocytes, Am. J. Cardiol. 80 (1997) 65Ae76A.
[8] D.D. Habets, W.A. Coumans, P.J. Voshol, M.A. den Boer, M. Febbraio, A. Bonen,
J.F. Glatz, J.J. Luiken, AMPK-mediated increase in myocardial long-chain fatty
acid uptake critically depends on sarcolemmal CD36, Biochem. Biophys. Res.
Commun. 355 (2007) 204e210.
[9] S. Zhang, S. Chen, Y. Shen, D. Yang, X. Liu, A.C. Sun-Chi, H. Xu, Puerarin induces
angiogenesis in myocardium of rat with myocardial infarction, Biol. Pharm.
Bull. 29 (2006) 945e950.
[10] X.P. Wu, J.G. Feng, H.M. Chen, F. Cheng, L. Zhang, Z. Wei, W. Chen, Protective
effects of puerarin against myocardial injury in patients with hypertension
during perioperational period, Zhongguo Zhong Xi Yi Jie He Za Zhi 26 (2006)
255e257.
[11] F.L. Xiong, X.H. Sun, L. Gan, X.L. Yang, H.B. Xu, Puerarin protects rat pancreatic
islets from damage by hydrogen peroxide, Eur. J. Pharmacol. 529 (2006) 1e7.
[12] F.L. Hsu, I.M. Liu, D.H. Kuo, W.C. Chen, H.C. Su, J.T. Cheng, Antihyperglycemic
effect of puerarin in streptozotocin-induced diabetic rats, J. Nat. Prod. 66
(2003) 788e792.
[13] L.N. Hao, Y.Q. Ling, X.M. Luo, Y.X. Mao, Q.Y. Mao, S.Z. He, Y.L. Ling, Puerarin
decreases lens epithelium cell apoptosis induced partly by peroxynitrite in
diabetic rats, Sheng Li Xue Bao 58 (2006) 584e592.
[14] T. Nakamura, T. Terajima, T. Ogata, K. Ueno, N. Hashimoto, K. Ono, S. Yano,
Establishment and pathophysiological characterization of type 2 diabetic
mouse model produced by streptozotocin and nicotinamide, Biol. Pharm. Bull.
29 (2006) 1167e1174.
[15] N. Zhou, Y. Fu, Y. Wang, P. Chen, H. Meng, S. Guo, M. Zhang, Z. Yang, Y. Ge, p27
kip1 haplo-insufﬁciency improves cardiac function in early-stages of
W. Cheng et al. / Biochemical and Biophysical Research Communications 463 (2015) 1108e11141114myocardial infarction by protecting myocardium and increasing angiogenesis
by promoting IKK activation, Sci. Rep. 4 (2014) 5978.
[16] P. Chen, S. Pang, N. Yang, H. Meng, J. Liu, N. Zhou, M. Zhang, Z. Xu, W. Gao,
B. Chen, Z. Tao, L. Wang, Z. Yang, Beneﬁcial effects of schisandrin B on the
cardiac function in mice model of myocardial infarction, PLoS One 8 (2013)
e79418.
[17] S. Neubauer, The failing heartean engine out of fuel, N. Engl. J. Med. 356
(2007) 1140e1151.
[18] Q. Wang, T. Wu, X. Chen, J. Ni, X. Duan, J. Zheng, J. Qiao, L. Zhou, J. Wei,
Puerarin injection for unstable angina pectoris, Cochrane Database Syst. Rev.
(2006) CD004196.
[19] J. Wu, X. Zhang, B. Zhang, Efﬁcacy and safety of puerarin injection in treat-
ment of diabetic peripheral neuropathy: a systematic review and meta-
analysis of randomized controlled trials, J. Tradit. Chin. Med. 34 (2014)
401e410.
[20] R. Tian, E.D. Abel, Responses of GLUT4-deﬁcient hearts to ischemia underscore
the importance of glycolysis, Circulation 103 (2001) 2961e2966.
[21] L.M. Semeniuk, A.J. Kryski, D.L. Severson, Echocardiographic assessment of
cardiac function in diabetic db/db and transgenic db/db-hGLUT4 mice, Am. J.
Physiol. Heart Circ. Physiol. 283 (2002) H976eH982.
[22] C.T. Coburn, F.F. Knapp Jr., M. Febbraio, A.L. Beets, R.L. Silverstein,
N.A. Abumrad, Defective uptake and utilization of long chain fatty acids in
muscle and adipose tissues of CD36 knockout mice, J. Biol. Chem. 275 (2000)
32523e32529.
[23] A. Ibrahimi, A. Bonen, W.D. Blinn, T. Hajri, X. Li, K. Zhong, R. Cameron,
N.A. Abumrad, Muscle-speciﬁc overexpression of FAT/CD36 enhances fatty
acid oxidation by contracting muscle, reduces plasma triglycerides and fatty
acids, and increases plasma glucose and insulin, J. Biol. Chem. 274 (1999)
26761e26766.
[24] M. Eblenkamp, U. Bottcher, J. Thomas, C. Loken, I. Ionescu, H. Rose,
H. Kammermeier, Y. Fischer, The effect of anoxia on cardiomyocyte glucose
transport does not involve an adenosine release or a change in energy state,
Life Sci. 59 (1996) 141e151.
[25] T.A. Hacker, J.L. Hall, C.K. Stone, W.C. Stanley, Alanine, glutamate, and
ammonia exchanges in acutely ischemic swine myocardium, Basic Res. Car-
diol. 87 (1992) 184e192.
[26] W. Doehner, M. Frenneaux, S.D. Anker, Metabolic impairment in heart failure:
the myocardial and systemic perspective, J. Am. Coll. Cardiol. 64 (2014)
1388e1400.
[27] J.J. Luiken, Y. Arumugam, R.C. Bell, J. Calles-Escandon, N.N. Tandon, J.F. Glatz,
A. Bonen, Changes in fatty acid transport and transporters are related to theseverity of insulin deﬁciency, Am. J. Physiol. Endocrinol. Metab. 283 (2002)
E612eE621.
[28] D. An, B. Rodrigues, Role of changes in cardiac metabolism in development of
diabetic cardiomyopathy, Am. J. Physiol. Heart Circ. Physiol. 291 (2006)
H1489eH1506.
[29] T.A. Nicholl, G.D. Lopaschuk, J.H. McNeill, Effects of free fatty acids and
dichloroacetate on isolated working diabetic rat heart, Am. J. Physiol. 261
(1991) H1053eH1059.
[30] S.R. Wall, G.D. Lopaschuk, Glucose oxidation rates in fatty acid-perfused iso-
lated working hearts from diabetic rats, Biochim. Biophys. Acta 1006 (1989)
97e103.
[31] J.C. Chatham, J.R. Forder, Relationship between cardiac function and substrate
oxidation in hearts of diabetic rats, Am. J. Physiol. 273 (1997) H52eH58.
[32] J. Yang, N. Sambandam, X. Han, R.W. Gross, M. Courtois, A. Kovacs,
M. Febbraio, B.N. Finck, D.P. Kelly, CD36 deﬁciency rescues lipotoxic cardio-
myopathy, Circ. Res. 100 (2007) 1208e1217.
[33] D. Bridges, A.R. Saltiel, Phosphoinositides: key modulators of energy meta-
bolism, Biochim. Biophys. Acta 1851 (2015) 857e866.
[34] B.N. Finck, J.J. Lehman, T.C. Leone, M.J. Welch, M.J. Bennett, A. Kovacs, X. Han,
R.W. Gross, R. Kozak, G.D. Lopaschuk, D.P. Kelly, The cardiac phenotype
induced by PPARalpha overexpression mimics that caused by diabetes mel-
litus, J. Clin. Invest. 109 (2002) 121e130.
[35] J. Buchanan, P.K. Mazumder, P. Hu, G. Chakrabarti, M.W. Roberts, U.J. Yun,
R.C. Cooksey, S.E. Litwin, E.D. Abel, Reduced cardiac efﬁciency and altered
substrate metabolism precedes the onset of hyperglycemia and contractile
dysfunction in two mouse models of insulin resistance and obesity, Endo-
crinology 146 (2005) 5341e5349.
[36] S. Sharma, J.V. Adrogue, L. Golfman, I. Uray, J. Lemm, K. Youker, G.P. Noon,
O.H. Frazier, H. Taegtmeyer, Intramyocardial lipid accumulation in the failing
human heart resembles the lipotoxic rat heart, FASEB J. 18 (2004) 1692e1700.
[37] A. Kalinowska, J. Gorski, E. Harasim, D. Harasiuk, A. Bonen, A. Chabowski,
Differential effects of chronic, in vivo, PPAR's stimulation on the myocardial
subcellular redistribution of FAT/CD36 and FABPpm, FEBS Lett. 583 (2009)
2527e2534.
[38] M.E. Young, G.W. Goodwin, J. Ying, P. Guthrie, C.R. Wilson, F.A. Laws,
H. Taegtmeyer, Regulation of cardiac and skeletal muscle malonyl-CoA
decarboxylase by fatty acids, Am. J. Physiol. Endocrinol. Metab. 280 (2001)
E471eE479.
[39] P.J. Randle, P.B. Garland, C.N. Hales, E.A. Newsholme, The glucose fatty-acid
cycle. Its role in insulin sensitivity and the metabolic disturbances of dia-
betes mellitus, Lancet 1 (1963) 785e789.
